Clinical trial · Interventional
Satraplatin for Patients With Metastatic Breast Cancer (MBC)
Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC)
NCT00265655CI-TRIAL-00006611completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Satraplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine the objective response rate (ORR) of oral satraplatin in patients with metastatic breast cancer
- timeFrame
- 1 year
Secondary outcomes (5)
- measure
- To determine duration of response
- timeFrame
- 6 weeks
- measure
- To determine progression-free survival (PFS)
- timeFrame
- 1 year
- measure
- To determine 1-year survival
- timeFrame
- 1 year
- measure
- To evaluate the toxicities of satraplatin in MBC patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
1. Has cytologically or pathologically confirmed breast cancer that is metastatic 2. Must have had prior HerceptinÒ therapy if patient has HER2+ (overexpressing) breast cancer. HER2 is considered overexpressed if it is 3+ by IHC or if the gene is amplified by Flourescence in situ hybridization (FISH) 3. Has had no more than 1 prior chemotherapy regimen for MBC 4. Has had no prior platinum-based therapy 5. Has an ECOG Performance Status (PS) 0-2
References
Publications (0)
Data not yet available
No reference posted for this study.